Pacific Biosciences Of California (PACB) Gross Margin (2010 - 2026)

Pacific Biosciences Of California's Gross Margin history runs 17 years deep, the most recent figure standing at 34.54% for Q1 2026.

• In Q1 2026, Gross Margin rose 3823.0% year-over-year to 34.54%; the TTM figure through Mar 2026 stood at 37.49% (up 2132.0% YoY), while the FY2025 annual figure was 28.61%, up 440.0% from the prior year.
• Gross Margin was 34.54% for Q1 2026 at Pacific Biosciences Of California, down from 37.11% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 45.66% in Q2 2022 to a low of 3.69% in Q1 2025.
• Historically, Gross Margin has averaged 29.28% across 5 years, with a median of 32.15% in 2023.
• The sharpest annual moves came in 2025 and 2026: Gross Margin plunged 3276 bps in 2025, then soared 3823 bps in 2026.
• A 5-year view of Gross Margin shows it stood at 18.79% in 2022, then retreated by 13 bps to 16.4% in 2023, then jumped by 56 bps to 25.64% in 2024, then soared by 45 bps to 37.11% in 2025, then declined by 7 bps to 34.54% in 2026.
• The last three Gross Margin figures came in at 34.54% (Q1 2026), 37.11% (Q4 2025), and 41.36% (Q3 2025), per Business Quant data.